Jennifer Bolen, JD
A Division of the J. Bolen Group, LLC
Ms. Jennifer Bolen owns and operates The Legal Side of Pain®, a medico-legal consulting firm that specializing in the development and implementation of risk management programs and practice standards for the use of controlled substances to treat pain and the office-based treatment of opioid addiction. She also specializes in the development and presentation of educational materials related to state and federal controlled substance and pain act guidelines, laws, policies, and regulations, and HIPAA matters. In 2009, she will lead a new initiative called The Pain Lawyer™, where she and colleagues will begin a nationwide initiative to train legal counsel in key pain management and controlled substance prescribing issues.
In January 2006, the American Academy of Pain Medicine appointed Ms. Bolen to serve as Special Counsel to Academy Members. In addition, she is the legal editor for Pain Medicine News, serves on the editorial board for and publishes in Pain Medicine, and also publishes in The Journal of Opioid Management and Practical Pain Management. Ms. Bolen serves as guest faculty with the University of Florida’s College of Pharmacy, and co-teaches a course on Federal Regulation of Controlled Substances.
Ms. Bolen has presented hundreds of lectures and has also worked with several managed care organizations to develop and implement compliance policies related to the use of controlled substances to treat pain. Ms. Bolen authors regular legal columns and thousands of providers nationwide use her website regularly to stay current on legal/regulatory issues in pain management.
Jennifer Bolen has received consultant fees from Abbott Laboratories, Avee Laboratories, Inc., Capital Tox, Cephalon, Inc., King Pharmaceuticals, Inc., Meda Pharmaceuticals Inc., and Millennium Pharmaceuticals, Inc. as well as honoraria related speakers’ bureau activities from Calloway Labs, Capital Tox, Cephalon, and PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. She owns significant holdings in Abbott and King.